Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.
USD 29.95
Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.

Contact Information

Legal Address
Alembic Road, ,
Vadodara; Gujarat; Map
Postal Code: 390003
Tel: 228
Fax: 228

Full name: Alembic Pharmaceuticals Ltd.

Status: Listed
Legal Form: Public Limited Company
Operational Status: Operational
EMISid: 3267209
IN-CIN: U24230GJ2010PLC061123
ISIN: INE901L01018
Incorporation Date: 1907

Main Activities

Main Activities: Pharmaceutical and Medicine Manufacturing

Main Products

pharmaceutical products, pharmaceutical substances and Intermediates

Company Description

Alembic Pharmaceuticals Limited develops, manufactures and markets pharmaceutical products, pharmaceutical substances and Intermediates. The company is in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The company was established in 1907 and hast its office based in Vadodara.


Basic Information

Total Employees:
Outstanding Shares:
: ()
Registered Capital:
Financial Auditors:

EMIS Benchmark Score

View all parameters in Benchmark Score

Quote Chart

Quote Summary

Last Price 611.35
Volume 3,207
Turnover 1,965,971
Index    S&P CNX 500
Market Bombay Stock Exchange
Ticker 533573
Market Cap Market Cap 117,624,505
52 Week High 684.65
52 Week Low 526.90
Price to Earnings (P/E) 16.35
Earnings per Share (EPS) 38.16
Dividend Yield 2.5 (March 31, 2013)
Bookvalue 15,192,800
Enterprise Value 115,402,736
Quote updated on April 28, 2017
Note: data in INR Thousands.


2014: Imports INR 1,933,192.00 Thousands
Import connections ('000)
2014: Exports INR 7,501,748.00 Thousands
Export connections ('000)

Key Executives

Chairman & Managing Director

Ownership Details

Indian Promoters

Key Stats

Select Items to chart them. 2017 Q3C
Net sales revenue
Total operating revenue
Operating profit (EBIT)
Net Profit (Loss) for the Period
Total assets N/A
Total equity
Operating Profit (EBIT) Margin
Return on Sales (ROS)
Return on Equity (ROE)
Debt to Equity
Quick Ratio
Cash Ratio
Note: units in Thousands. Statement: Non-Audited, Consolidated
Source: Dion Global Solutions Limited, EMIS Company Database.


Competitors - India


EMIS DealWatch Deals

DealMonitor Deal Intents

for 29.95 USD
Payment methods include:
USD 29.95
Most recent financial data: 2016
Payment methods include:
The full PDF report for this company will be available to download immediately after purchase. The report will contain:
Company Tear Sheet
Contact Information
NAICS Industry Classification
Business description
Basic Information
Share Price information
Key Executives
Ownership Details
Subsidiaries and Affiliates
Key Financial Highlights
Financial Performance Charts
Latest M&A and ECM Deals
Top Competitors
Financial Statements
Annual Statements
EMIS Credit Analytics
EMIS Benchmark Score

- or -

EMIS company profiles are part of a larger information service that combines company, industry and country data and analysis for over 120 emerging markets on a unique information platform.

If you need broad and deep coverage of one or many countries, you may be interested in subscribing. Request a demonstration of our full service and one of our account managers will be in touch.

Register Your Interest